Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Skimmianine is a furoquinoline alkaloid primarily found in plants of the Rutaceae family. It exhibits analgesic, antispastic, sedative, and anti-inflammatory properties. Skimmianine acts as a strong acetylcholinesterase (AChE) inhibitor (IC50 = 8.6 μg/mL), which may contribute to its neuroprotective and immunomodulatory effects. It has also shown cytotoxicity against various cancer cell lines and genotoxicity in preclinical studies. The compound inhibits neuroinflammation by targeting the NF-κB activation pathway in microglia and protects neurons from toxicity induced by microglia-conditioned media[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on skimmianine.